SynthesisBMC public health2025
Prevalence and clinical characteristics of concurrent chronic hepatitis B and fatty liver disease in China: a systematic review and meta-analysis.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis.Hepatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth chronic hepatitis B (CHB) and fatty liver disease (FLD) are major contributors to the burden of severe liver diseases. China bears the heaviest burden of CHB worldwide, while the prevalence of FLD has been substantially increased in the last decades. However, the prevalence and clinical impact of concurrent CHB and FLD in China remain unclear, impeding effective prevention and management of severe liver diseases.
methodsWe conducted a systematic review and meta-analysis on prevalence and clinical characteristics of concurrent CHB and FLD in China. Eligible literatures were retrieved from Medline, EmBase, Web of Science, WanFang and China National Knowledge Infrastructure (CNKI), up to 31 December 2023. The pooled prevalence was estimated using a random-effects model. The weighted mean difference was calculated to compare the clinical characteristics across different groups.
resultsA total of 114 studies with 318,770 participants were included for the analysis. The pooled prevalence of CHB with concurrent FLD in the general population was 1.48% (95% CI: 1.02%-2.14%). The pooled prevalence of FLD in CHB patients was 26.75%, while the pooled prevalence of CHB in FLD patients was 16.94%. The co-morbidity group exhibited higher levels of body mass index (BMI), triglycerides, fasting insulin and albumin than the CHB group. The total cholesterol level in the co-morbidity group was 0.48mmol/L lower than the FLD group. Additionally, it demonstrated a significantly lower hepatitis B virus DNA load and higher prevalence of diabetes, hypertension, and hyperuricemia than the CHB group.
conclusionsThe co-occurrence of CHB and FLD is an emerging public health concern in China, showing distinct clinical characteristics compared to those with CHB or FLD alone. Our study highlights an urgent need of tailored prevention and treatment strategies for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.